Pembrolizumab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Differentiated Thyroid Cancer

Conditions

Differentiated Thyroid Cancer

Trial Timeline

Dec 20, 2024 → Dec 1, 2027

NCT ID

NCT05852223

About Pembrolizumab

Pembrolizumab is a phase 2 stage product being developed by Merck for Differentiated Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05852223. Target conditions include Differentiated Thyroid Cancer.

What happened to similar drugs?

1 of 8 similar drugs in Differentiated Thyroid Cancer were approved

Approved (1) Terminated (1) Active (6)

✅sunitinibPfizerApproved

🔄Abemaciclib + PlaceboEli LillyPhase 3

🔄Lenvatinib + PlaceboEisaiPhase 3

❌Selumetinib + Placebo + Radioactive Iodine TherapyAstraZenecaPhase 3

🔄Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placeboNovartisPhase 3

🔄Vandetanib (SAR390530) + PlaceboSanofiPhase 3

🔄Thyrogen (thyrotropin alfa for injection)SanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02083484	Pre-clinical	Completed	—	—	Melanoma
NCT07302347	Phase 1/2	Recruiting	Mar 31, 2026	Dec 31, 2029	Malignant Neoplasm
NCT07089992	Phase 2	Recruiting	Dec 4, 2025	Dec 1, 2028	Sarcoma
NCT07007273	Phase 2	Recruiting	Jun 20, 2025	Jul 1, 2030	Cutaneous Sarcoma
NCT04569461	Phase 2	Withdrawn	Jun 1, 2025	Dec 1, 2026	Prostate Cancer
NCT05815927	Phase 3	Recruiting	May 23, 2025	Mar 30, 2030	Oligometastatic Squamous Cell Carcinoma of the Head and Neck
NCT05852223	Phase 2	Recruiting	Dec 20, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT05879120	Phase 2	Withdrawn	Jul 30, 2024	Oct 2, 2024	Recurrent Glioblastoma
NCT06004336	Phase 2	Recruiting	Oct 31, 2023	Jan 1, 2029	Oligometastatic Renal Cell Carcinoma
NCT05496036	Phase 2	Recruiting	Feb 13, 2023	Sep 30, 2027	Merkel Cell Carcinoma
NCT05131919	Phase 2	Active	Dec 22, 2022	Jul 1, 2031	Colorectal Cancer
NCT05197322	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2028	Adenocarcinoma of the Colon
NCT05406713	Phase 2	Active	Jul 13, 2022	Jan 1, 2028	Muscle Invasive Bladder Carcinoma
NCT05025813	Phase 2	Recruiting	Jun 28, 2022	Jun 1, 2027	Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT06413095	Phase 1	Completed	Jun 1, 2022	Jun 22, 2023	Head and Neck Squamous Cell Carcinoma
NCT05191472	Phase 2	Terminated	May 3, 2022	Dec 31, 2023	Multiple Myeloma
NCT05204160	Phase 2	Withdrawn	Apr 11, 2022	Feb 27, 2024	Plasma Cell Myeloma
NCT04575961	Phase 2	Active	Feb 22, 2022	Mar 1, 2028	Ovarian Cancer
NCT04417166	Phase 2	Recruiting	Feb 11, 2022	Dec 1, 2026	Lymphoma, Extranodal NK-T-Cell
NCT05188508	Phase 2	Recruiting	Jan 14, 2022	Jan 1, 2027	Glioma

Competing Products

20 competing products in Differentiated Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	22
Abemaciclib + Placebo	Eli Lilly	Phase 3	44
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
Selpercatinib Monotherapy	Eli Lilly	Phase 2	42
Selumetinib + Placebo + Radioactive Iodine Therapy	AstraZeneca	Phase 3	32
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin	Merck	Phase 2	42
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Everolimus + Sorafenib	Novartis	Phase 2	31
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo	Novartis	Phase 3	44
PDR001	Novartis	Phase 2	35
Everolimus (Afinitor®)	Novartis	Phase 2	35
Sacituzumab govitecan	Gilead Sciences	Phase 2	42
sunitinib	Pfizer	Approved	43
Vandetanib (SAR390530) + Placebo	Sanofi	Phase 3	40
Thyrogen (thyrotropin alfa for injection)	Sanofi	Phase 3	40
Cabazitaxel	Sanofi	Phase 2	35
Larotrectinib monotherapy	Bayer	Phase 2	39